• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc. (Amendment)

    2/9/23 11:32:50 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    SC 13G/A 1 tv01991-supernuspharmaceutic.htm SCHEDULE 13G/A supernuspharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  Supernus Pharmaceuticals Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  868459108

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  868459108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    34,447

    7.  SOLE DISPOSITIVE POWER

    5,703,846

    8.  SHARED DISPOSITIVE POWER

    86,114

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,789,960

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.71%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Supernus Pharmaceuticals Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    9715 Key West Avenue
    Rockville, MD 20850

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    868459108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $SUPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    10/9/2025$65.00Neutral → Overweight
    Piper Sandler
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Supernus Pharmaceuticals Inc.

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/18/26 5:18:35 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO Khattar Jack A. acquired 12,500 shares, disposed of 12,500 shares and sold $1,763,124 worth of shares (35,000 units at $50.37), increasing direct ownership by 1% to 1,241,144 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/16/26 4:08:19 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hudson Frederick M. sold $271,725 worth of shares (5,369 units at $50.61), decreasing direct ownership by 8% to 60,413 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    3/16/26 4:07:41 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Pharmaceuticals to Participate in June Investor Conferences

    ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences: 2026 Jefferies Global Healthcare ConferenceDate:Fireside chat:Place:Webcast Link:Wednesday, June 3, 202610:30 a.m. ETMarriott Marquis, New York, NYHere  Goldman Sachs 47th Annual Global Healthcare ConferenceDate:Place:Monday, June 8, 2026Loews Miami Beach, Miami Beach, Fla.   Investors interested in arranging a meeting with the Company's management during these confere

    5/27/26 4:30:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

    ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV. Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be

    5/6/26 5:00:52 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Announces First Quarter 2026 Financial Results

    Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.The Company reiterates full year 2026 financial guidance. ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical

    5/5/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $65.00

    10/9/25 8:22:44 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    SEC Filings

    View All

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/20/26 4:37:01 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Supernus Pharmaceuticals Inc.

    10-Q - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/5/26 4:15:14 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    5/5/26 4:09:54 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Financials

    Live finance-specific insights

    View All

    Supernus Announces First Quarter 2026 Financial Results

    Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Regulatory submission to the FDA for second supplier for ONAPGO expected in third quarter 2026, with potential approval by mid-year 2027.The Company reiterates full year 2026 financial guidance. ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical

    5/5/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

    ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m. ET to discuss these results. Following management's prepared remarks and discussion of business results, the call will be open for questions. A live webcast will be acces

    4/22/26 4:15:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

    Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025. New patient initiation for ONAPGO resumed in the first quarter of 2026. Full

    2/24/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

    4/20/26 5:00:00 PM ET
    $ACOG
    $KALV
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    10/16/23 5:34:21 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

    SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    10/31/24 11:55:00 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care